BTG unrattled by venomous reports
This article was originally published in Scrip
Executive Summary
BTG has told Scrip that contrary to a recent media report, none of the venom it uses to produce CroFab – its antidote for rattlesnake bites – is obtained from "rattlesnake roundups," a practice which has come under scrutiny in the US. A pro-roundup activist had suggested that banning these organized hunts, such as the roundup held annually in Sweetwater, Texas, would cut off the supply of venom to BTG which it needs to make the antidote.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.